Article Text

Download PDFPDF
Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs
  1. H. A. Benchaoui, DVM, PhD1,
  2. E. M. Siedek, MedVet, PhD, MRCVS1,
  3. V. A. De La Puente-Redondo, DVM, PhD1,
  4. N. Tilt, BSc, MSc, CStat1,
  5. T. G. Rowan, BVSc, PhD, MIBiol, MRCVS1 and
  6. R. G. Clemence, BSc, MSc, PhD1
  1. 1 Pfizer Animal Health, Veterinary Medicine Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ


Maropitant is a neurokinin-1 inhibitor that acts to prevent and treat vomiting by blocking stimuli to the final common pathway in the emetic centre of the brain. The field efficacy and safety of a single oral dose of maropitant were investigated for the prevention of vomiting in dogs with a history of motion sickness resulting from transportation by car in two blinded, placebo-controlled studies. In an exploratory study designed as a two-way crossover trial with 17 dogs, 10 of the dogs given the placebo vomited during a car journey but only three of the dogs vomited under maropitant treatment. In a larger multicentred parallel design study, 69 of 105 dogs treated with the placebo vomited during the journey compared with 15 of 106 dogs treated with maropitant (P≤0·0001).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.